Key statistics
On Monday, Spyre Therapeutics Inc (SYRE:NSQ) closed at 42.49, -7.15% below its 52-week high of 45.76, set on Feb 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 41.27 |
|---|---|
| High | 42.93 |
| Low | 40.74 |
| Bid | 40.01 |
| Offer | 44.27 |
| Previous close | 43.01 |
| Average volume | 869.23k |
|---|---|
| Shares outstanding | 78.54m |
| Free float | 70.21m |
| P/E (TTM) | -- |
| Market cap | 3.38bn USD |
| EPS (TTM) | -2.37 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Spyre Therapeutics to Participate in Upcoming March Investor Conferences
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
- Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
- Spyre Therapeutics to Participate in Upcoming November Investor Conferences
- Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
- Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
More ▼
